CDC Panel Backs RSV Vaccine for Seniors
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, June 22, 2023 -- An advisory panel of the U.S. Centers for Disease Control and Prevention voted on Wednesday to recommend the first RSV vaccines for seniors.
The U.S. Food and Drug Administration has already approved the vaccines, one made by GlaxoSmithKline called Arexvy and a version from Pfizer called Abrysvo.
During the meeting, the panel called for "shared clinical decision-making" between doctors and patients to discuss benefits and risks, but stopped short of recommending that all seniors get the shots.
Younger seniors, those in their early 60s, will have fewer risks for severe disease from the virus, CBS News reported. The vaccine trials did have a small number of very rare, but severe, "inflammatory neurologic events." CDC officials plan to closely follow data from vaccine safety systems as seniors begin getting the RSV vaccines.
"I want to remind everyone that we have one of the best vaccine safety systems in the world. We have the ability to rapidly acquire information, rapidly assess it and act on it. We saw that during the COVID pandemic, that system is viable and is in place," José Romero, M.D., director of the CDC National Center for Immunization and Respiratory Diseases, told the panel, CBS News reported.
Prices have not been finalized, but GSK has said its vaccine could carry a price tag of $200 to $295 per dose. Pfizer has said its shot will be between $180 and $270, CBS News reported.
For more information see What is the difference between Arexvy and Abrysvo?
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Personalized Tool Can Predict Infants at Increased Risk for RSV
THURSDAY, May 9, 2024 -- A personalized tool can predict infants at increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) who would...
Most Moms-to-Be Interested in RSV Vaccination During Pregnancy
THURSDAY, April 25, 2024 -- More than half of women who are pregnant or planning to become pregnant are very likely to get vaccinated against respiratory syncytial virus (RSV)...
RSV Burden in Children Under 5 Increased in 2021 and 2022 Versus 2015-2019
FRIDAY, April 19, 2024 -- For children younger than 5 years, the incidence of respiratory syncytial virus (RSV) hospitalization increased in 2021 and 2022 compared with 2015 to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.